Coherus Looks To Put Udenyca Supply Issues In The Rearview Mirror

Pegfilgrastim Biosimilar Sales Double In Q3, Ahead Of CMO-Related Disruption

 
• By Dean Rudge

Coherus BioSciences will have to weather the storm of supply interruptions for its sole biosimilar product, Udenyca, in the final quarter of 2024.

More from Biosimilars

More from Generics Bulletin